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Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-
stage kidney failure, but is often identified early and therefore amenable to timely 
treatment. Interventions known to postpone the need for renal replacement therapy 
(RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with 
inconclusive results. To help resolve this we determined changes in RRT incidence 
rates as an indicator for increasing effective renoprotection over time in ADPKD. 
Methods
We analyzed data from the European Renal Association-European Dialyses and 
Transplant Association Registry on 315,444 patients starting RRT in 12 European 
countries between 1991 and 2010, grouped into four 5-year periods. 
Results
Of them, 20,596 were due to ADPKD. Between the first and last period the mean age 
at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted 
incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 
8.3 per million population. No change over time was found in the incidence of RRT 
for ADPKD up to age 50, whereas in recent time periods the incidence in patients 
above the age of 70 clearly increased. Among countries there was a significant 
positive association between RRT take-on rates for non-ADPKD kidney disease 
and ADPKD. 
Conclusion
Thus, the increased age at onset of RRT is most likely due to an increased access 
for elderly ADPKD patients or lower competing risk prior to the start of RRT rather 
than the consequence of effective emerging renoprotective treatments for ADPKD.
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INTRODUCTION
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common 
heritable kidney disease, affecting approximately 1 in every 1000 subjects.1 
Most affected subjects show progressive renal function decline and need renal 
replacement therapy (RRT) between their 40th and 70th year of age.2-4 
Over the past decades several treatment options have emerged to postpone the 
need for RRT in subjects with chronic kidney disease, such as strict blood pressure 
control, RAAS inhibition and low protein diets. These treatment options have also 
been tested in subjects with ADPKD with disappointing results.5-7 However, the 
results obtained in ADPKD studies should be interpreted with caution, since these 
studies were in general insufficiently powered to reach definitive conclusions 
(79, 89 and 200 patients, respectively). Furthermore, the ADPKD patients that 
were included were often still in the phase of their disease where renal function is 
relatively stable. In such patients it is difficult to study the renoprotective efficacy 
of interventions. Therefore, a conclusive answer to the question whether the 
conventional renoprotective regimens are effective in ADPKD patients is still lacking. 
Interestingly, two observational studies have suggested that in ADPKD patients 
the average age of onset of end-stage renal disease has increased considerably 
during the last two decades.8,9 This finding has been interpreted as that effective 
renoprotective therapies have emerged for ADPKD, with especially males having 
achieved a better prognosis. However, these observational studies were performed 
in relatively small patient populations (513 and 693 patients, respectively) which 
may have led to publication bias. 
It is surprising to note that the epidemiology of renal replacement therapy for 
ADPKD has seldom been studied, especially because ADPKD is one of the most 
common causes of end-stage renal disease. Given these considerations we used 
the European Renal Association - European Dialyses and Transplant Association 
(ERA-EDTA) Registry data to provide the largest epidemiological dataset on ADPKD 
yet. We used these data to study change in incidence rate of RRT, and average age 
and treatment modality at onset of RRT. The hypothesis of this study was that with 
a stable prevalence of ADPKD in the general population, change in incidence rates 
of RRT may provide indications whether renoprotective treatments have emerged 




This study was conducted using data of RRT patients participating in the ERA-
EDTA Registry. Details of this study protocol have been published elsewhere.10 In 
summary, 24 national and regional registries from 12 countries within Europe are 
participating, covering a population of 208 million people. Individual patient data, 
including date of birth, sex, primary kidney disease, treatment modality history 
(hemodialysis, peritoneal dialysis and transplantation), and date and cause of 
death were derived from the national registries of Austria, Denmark, Finland, France, 
Greece, Romania, Sweden, the Netherlands and England, Wales, Northern Ireland, 
Scotland (the United Kingdom), and from the regional registries of Dutch and 
French-speaking Belgium, Calabria (Italy), Andalusia, Aragon, Asturias, Basque 
country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, 
Galicia, and Valencian region (Spain). Additionally, we combined the individual 
and aggregated data, which were derived from Estonia, Latvia, Poland, Slovakia 
and Slovenia, for the incidence rate of RRT for ADPKD versus for non-ADPKD. 
Information on all RRT patients was used, except for Belgium, Spain (Cantabria, 
Castile and Leon and Castile-La Mancha) and the United Kingdom (except 
Scotland) from whom only information on patients >20 years of age was provided. 
As ADPKD patients rarely reach end-stage renal disease before this age, this 
limitation was not expected to influence results on prevalence of RRT for ADPKD. 
Registries from the following countries/regions provided complete information 
for all years within the study period: Andalusia (Spain), Austria, Basque country 
(Spain), Catalonia (Spain), Denmark, Finland, French-speaking Belgium, Greece, 
Sweden, Scotland, the Netherlands, and Valencia (Spain). For Belgium, Spain and 
the United Kingdom (except Scotland that provided complete data for the whole 
period), participation rates increased over time. Information on participation rates 
is shown in Supplementary Table 1.
Definition
Incidence of RRT was defined as the number of patients starting on any modality 
of RRT annually at day 1, whereby the type of modality on which they started was 
assessed at day 91. Incidence rate per million population (pmp) was calculated 
by dividing the observed count by the mid-year population. Primary renal disease 
for which RRT was started was coded using the ERA-EDTA coding system.11 Two 
ERA-EDTA primary renal disease codes can be used for the diagnosis of ADPKD: 
40 (unspecified polycystic kidney disease) and 41 (polycystic kidney disease adult 
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type). Among countries, a substantial variation (0.2% to 2.7%) in incidence of code 
40 was observed (see Supplementary Table 2). We combined the codes 40 and 41 
for the definition ADPKD, because the incidence of non-ADPKD polycystic kidney 
disease is expected to be very low and unlikely to account for figures such as 2.7%. 
Data analysis
The incidences of treatment modality of ADPKD patients treated with RRT were 
compared to similar study parameters in non-ADPKD patients (all other RRT 
patients). Incidence of RRT was studied in four consecutive 5-year periods (1991-
1995, 1996-2000, 2001-2005, and 2006-2010). For each period, we calculated 
the incidence for ADPKD as the number of patients starting RRT annually in 
5 subsequent years, divided by the sum of the total population in the same 5 
years. The age and sex distribution of the 2005 EU27 population, as provided by 
Eurostat,12 was used to adjust for age and sex, to allow evaluation of trends in time 
and population differences among countries. Average data in figures and tables 
are calculated taking into account only data from registries/countries with complete 
follow-up during all four study periods, unless stated differently. 
To investigate the association between incidences of RRT for ADPKD versus for 
non-ADPKD and to calculate corresponding p-values, we used weighted least 
squares regression analysis that takes country specific sample sizes into account. 
Regression analyses were carried out using SPSS version 20. To investigate the 
association between age and incidence of RRT, we plotted the number of ADPKD 
patients that started RRT per age category. We used t-tests and ANOVAs to study 
differences in mean age at start of RRT over time and between males and females. 
For an earlier study, data were collected on the last serum creatinine assessed 
in the 0-4 weeks before the start of dialysis. The registries of Dutch-speaking and 
French-speaking Belgium, Valencia (Spain), Finland, Greece, Basilicata (Italy), 
Piedmont (Italy) and United Kingdom (Scotland) participated. Details of this study 
have been published elsewhere.13
RESULTS
Incidence rate of RRT
Between 1991 and 2010 a total of 314,176 patients from 12 countries started 
RRT; of these patients 20,483 had ADPKD as cause of kidney failure and 293,693 
patients other kidney diseases. 54% of ADPKD patients were male and 62% of non-
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ADPKD patients. Over this time period the crude incidence rate of RRT for ADPKD 
increased from 6.9 to 8.4 pmp. Table 1 shows the international variation in the 
age- and sex-adjusted RRT incidence rate of ADPKD subjects, which is in the most 
recent period ranging from 5.3 per million of the population (pmp) in Romania to 
10.0 pmp in Belgium. Figure 1 visualises these differences in RRT incidence rates 
for ADPKD geographically. 
Trends in incidence rate of RRT
Although, the relative contribution of ADPKD to the total incident RRT population 
decreased from 7.7 % in 1991-1995 to 6.1 % 2006-2010 (Supplementary Figure 1), 
the average age- and gender- adjusted incidence rate has increased by 9.2% from 
7.6 pmp in 1991-1995 to 8.3 pmp in 2006-2010 (Table 1). Differences in trends were  24 
RRT incidence 2006-2010:  ADPKD patients
adjusted for age and gender distribution EU27 population
< 7.2 pmp
7.2 - 9.0 pmp
> 9.0 pmp
EU27 country, but no data available
non-EU27 country
 
Figure 1. Incidence rate of renal replacement therapy (RRT) for ADPKD in member states of 
the EU27. Data are expressed per million of the population (pmp) and adjusted for age and 



















Figure 1. Incidence rate of renal replacement therapy (RRT) for ADPKD in member states of the EU27. 
Data are expressed per million of the population (pmp) and adjusted for age and sex to the 2005 EU27 
population. Data are the average values for the time period 2006-2010.
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observed among countries, with the Netherland and Italy showing a slight decrease 
and other countries showing an increase over time.
Table 1. Incidence rate of renal replacement therapy for ADPKD at day 1, and incidence rate of 
dialysis (hemodialysis and peritoneal dialysis) or kidney transplantation as primary modality of 
RRT at day 91 (middle and lower panel, respectively). Rates are standardised for age and sex to 












Austria 6.8 8.1 8.0 7.3 +7.4
Belgium* 6.9 9.4 8.9 10.0 NA
Denmark 7.2 8.0 8.2 8.1 +12.5
Finland 6.5 8.5 7.8 7.1 +9.2
France 9.4 NA
Greece 6.4 7.4 8.1 7.6 +18.8
Italy, Calabria 7.6 9.3 7.4 -2.7
Romania 5.3 NA
Spain* 9.6 10.4 9.3 9.2 NA
Sweden 8.6 8.7 8.7 9.1 +5.8
The Netherlands 7.6 7.2 7.7 7.1 -6.6
United Kingdom* 5.9 6.4 6.4 7.1 NA
All countries+ 7.6 8.5 8.5 8.3 +9.2
Dialysis
Austria 6.5 7.5 7.5 6.5 0.0
Belgium* 6.6 8.6 8.5 9.2 NA
Denmark 6.0 7.2 7.4 7.3 +21.7
Finland 6.0 8.4 7.6 6.9 +15.0
France 7.9 NA
Greece 6.3 7.4 7.8 7.3 +15.9
Italy, Calabria 7.3 8.7 6.9 -5.4
Romania 5.0 NA
Spain* 9.3 10.0 8.9 8.5 NA
Sweden 7.5 7.8 7.5 7.8 +4.0
The Netherlands 7.3 6.9 7.2 6.0 -17.8
United Kingdom* 5.5 5.9 5.8 5.9 NA
All countries+ 7.2 8.0 8.0 7.5 +4.2
Kidney transplantation
Austria 0.2 0.3 0.3 0.6 +200
Belgium* 0.3 0.5 0.2 0.5 NA
Denmark 0.9 0.6 0.5 0.7 -22.2
Finland 0.4 0.1 0.2 0.1 -75.0
France 1.3 NA
Greece 0.0 0.0 0.1 0.2 NA
Italy, Calabria 0.0 0.0 0.1 NA
Romania 0.1 NA
Spain* 0.0 0.3 0.3 0.5 NA
Sweden 0.9 0.7 0.9 1.1 +22.2
The Netherlands 0.3 0.2 0.5 1.0 +233
United Kingdom* 0.1 0.4 0.5 1.1 NA
All countries+ 0.3 0.3 0.4 0.7 +133
NA, not applicable or available (due to change in coverage over time)
*Coverage of the general population by the renal registry increasing over time, see 
for details Supplementary Table 1.
+ Average of countries with complete coverage during all 4 study periods.
# Change between 1991-1995 and 2006-2010.
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Age, sex and eGFR at start of RRT
Table 2 shows country specific data and the mean age at onset of RRT for ADPKD 
patients for each of the four study periods. We observed an increase in the mean 
age at start of RRT from 56.6 to 58.0 years (p<0.001). The mean age at onset of 
RRT was significantly higher in women than in men in all time periods (p<0.001). 
From 1991 to 2010 the mean age increased on average by 1.4 year in men and by 
1.5 year women. In non-ADPKD patients, the mean age at start RRT increased from 
57.6 to 64.7 years (p<0.001). Over time the age-adjusted male/female ratio of RRT 
incidence for ADPKD has remained stable (1.19, 1.28, 1.20 and 1.20, respectively). 
The additional analyses of eGFR data collected for an earlier study showed for the 
subgroup of ADPKD patients that the average estimated glomerular filtration rate 
(eGFR) in ADPKD patients at onset of dialysis increased only slightly (by 0.6 ml/
min/1.73m2, from 7.2 to 7.8 ml/min/1.73m2) in 2003 compared to 1999.   
Table 2. Mean age (in years) of ADPKD and non-ADPKD patients starting renal replacement 
therapy, country specific data and average (for which only countries are taken into account with 
complete coverage during all 4 study periods.
1991-1995 1996-2000 2001-2005 2006-2010
All RRT for ADPKD
Austria 57.4 59.1 58.6 59.5
Belgium* 58.1 58.2 59.5 58.9
Denmark 55.6 58.1 60.0 59.9
Finland 54.0 57.3 57.3 58.3
France 58.9
Greece 55.1 56.7 58.1 58.9
Italy. Calabria 61.5 59.8 60.2
Romania 55.9
Spain* 56.8 57.6 58.0 57.6
Sweden 58.7 57.9 60.6 58.2
The Netherlands 56.5 56.2 56.7 58.4
United Kingdom* 54.9 55.5 56.5 55.5
All countries+ 56.6 57.4 58.2 58.0
- Female 57.1 58.4 58.7 58.6
- Male 56.1 56.5 57.7 57.5
All RRT for non-ADPKD
All countries+ 57.6 60.8 63.5 64.7
- Female 57.9 61.4 64.1 62.5
- Male 57.3 60.4 63.1 64.5
* Coverage of the general population by the renal registry increasing over 
time, see for details Supplementary Table 1.
+ Average of countries with complete coverage during all 4 periods.
Trends in incidence rate of RRT by age
Figure 2 shows the incidence rate of RRT for ADPKD per age group for each of 
the four study periods. Importantly, there was no change in the incidence rate in 
subjects up to 50 years of age. Only the incidence rate in subjects older than 70 
years of age increased. Over the four study periods the incidence rate in subjects 
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younger than 30 years remained stable at less than 0.5 pmp (Supplementary Figure 
2). Similarly, the incidence rates remained fairly stable or changed minimally in 
patients in their third to sixth decade of life: 3.0 to 3.1 pmp, 11.9 to 12.8 pmp, 19.0 
to 18.8 pmp and 17.0 to 17.5 pmp, respectively, when comparing the time periods 
1991-1995 and 2006-2010. In contrast for the patients aged 70-79 and above 80 
years, the incidence has increased from 14.3 to 17.3 pmp and from 3.0 to 9.2 pmp. 
In both age groups a plateau was reached during the last study period (2006-2010) 
(Supplementary Figure 2).
Incidence and treatment modality at start of RRT in ADPKD versus non-ADPKD
Figure 3 shows the association between the incidence rates of RRT for ADPKD and 
for non-ADPKD patients in the time period 2006-2010. It indicates that countries with a 
high take-on rate for RRT in general, also have a high take-on rate for ADPKD patients. 
In an additional analysis including only patients older than 70 years of age also a 
positive association was found between ADPKD and non-ADPKD patients (R2 = 
0.651, β = 0.02 (95% CI 0.01 - 0.02, p=0.002). This indicates that countries with a 
high take-on rate for elderly non-ADPKD patients also have a high take-on rate for 
elderly ADPKD patients. During the four study periods, the age- and sex-adjusted 
























































Figure 2. Incidence rate of renal replacement therapy for ADPKD per age group. Data are expressed 
per million of the age related population (pmarp) and given for four consecutive study periods.
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Table 3. Trends over time in treatment modality on which ADPKD patients start renal replacement 
therapy. Percentages are standardized for age and sex to the 2005 EU27 population.
1991-1995 1996-2000 2001-2005 2006-2010 Change #
ADPKD % % % % %
Hemodialysis 73.6 77.3 74.2 70.1 -4.8
Peritoneal dialysis 22.4 19.3 21.5 21.6 -3.6
Kidney transplant recipients 3.9 3.4 4.4 8.1 +108
- Living donor 1.3 1.7 2.8 5.6 +319
- Deceased donor 2.4 1.5 1.5 2.3 -1.7
- Unknown donor 0.2 0.3 0.1 0.2 +8.7
Non-ADPKD
Hemodialysis 74.9 77.2 79.9 79.4 +6.0
Peritoneal dialysis 22.5 20.5 17.7 16.7 -25.8
Kidney transplant recipients 2.6 2.3 2.3 3.8 +46.2
- Living donor 1.1 1.2 1.4 2.6 +130
- Deceased donor 1.2 1.0 0.8 1.0 -17.7
- Unknown donor 0.2 0.2 0.1 0.2 0.0
For these data only countries were taken into account with complete coverage during all 4 periods.
# Change between 1991-1995 and 2006-2010.
73.6 to 70.1% from 1991 to 2010 (Table 3), whereas peritoneal dialysis remained 
stable at approximately 22% and transplantation increased from 3.9% to 8.1%. 
Figure 4 shows that ADPKD patients start RRT as often on peritoneal dialysis as 








































β! =!0.03 (95%CI 0.01-0.05)!












Figure 3. Incidence rate of renal replacement therapy for ADPKD versus for non-ADPKD. Data are the 
average values during the time period 2006-2010 and expressed per million population. The size of 
markers denotes the size of the population under study. Abbreviations are AT, Austria; BE, Belgium; DK, 
Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; IT, Italy, Calabria; Poland, PL; Portugal, PO; 
Latvia, LT; NL, The Netherlands; RO, Romania; SE, Sweden; SL, Slovenia; SK, Slovakia; ET, Estonia; UK, 
United Kingdom.
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is more often the initial treatment modality in ADPKD than in non-ADPKD patients. 
A similar trend is observed for patients receiving kidneys transplantation from living 
donors as well as deceased donors (Supplementary Figure 3).
DISCUSSION
This study shows that the incidence rate of RRT and the age at onset of RRT for 
ADPKD have slightly increased. Importantly, for ADPKD patients up to 50 years of 
age the RRT incidence rate expressed per million of the age related population has 
remained stable, whereas at older age an increase was observed. Furthermore, a 
positive association was found between the RRT incidence rate for ADPKD and 
for non-ADPKD patients. We interpret these findings as that this may be due to 
more elderly starting RRT, rather than that this was the consequence of effective 
renoprotective treatments having emerged for ADPKD.
Two observational studies have addressed this issue previously. Data from the 
University of Colorado Health Sciences Center suggested that recent ADPKD 
patients have a significant slower rate of ADPKD progression.8 In this study the 
average median survival time to RRT was investigated in two cohorts of patients, 
(i.e. 1985 - 1992 versus 1992 - 2001). The average age at start of RRT increased 
substantially for both male and female patients (from 53 to 63 years, and from 57 
to 61 years, respectively). A Danish population study showed that the incidence 
rate increased from 6.45 pmp to 7.59 pmp in a period of 17 years (1990-2007) 
and that the age at starting RRT also increased (from 55.9 to 60.6 years).9 The 
former study was relatively small with only 513 ADPKD patients included, and the 
baseline characteristics of the two studied cohorts differed, suggesting that the later 
cohort may have had a milder form of ADPKD. The Danish study reported country-
wide data. However, given the fact that ADPKD has a population prevalence of 
1:1000 and that ADPKD is a slowly progressive disease, the number of ADPKD 
patients that started RRT during the study period was still relatively low (n=693), 
and consequently did not allow us to reliably report RRT incidence data per age 
group. In line with the aforementioned literature, the present study showed that the 
age at onset RRT has increased during the last decades, albeit considerably less 
(from 56.6 to 58.0 years) than reported previously. Of note, a recent study from the 
Catalan registry that is included in the present report showed no change in age 
at onset of RRT. 14 Furthermore, we also observed that the age- and sex-adjusted 
RRT incidence rate increased for ADPKD by 9.2% during the four study periods. 
Importantly, we established that the incidence rate of RRT for ADPKD remained 
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stable up to 50 years of age and increased only in subjects aged 70 years and 
older. 
The combination of an increase in incidence rate of RRT and an increase in age at 
onset of RRT may be interpreted in various ways. This combination may suggest 
that overall as well as kidney prognosis has improved in ADPKD patients. However, 
it may also be that specifically more elderly are starting RRT nowadays. If effective 
renoprotective treatment had emerged during the last two decades in ADPKD, it 
would be expected that the entire curve of the incidence rate per million of the 
age related population would have shifted to the right for the most recent study 
periods, because renoprotective treatments would affect all age groups. However, 
we found no change in the incidence rate up to 50 years of age. This age group is 
thought to reflect the true incidence rate of kidney failure. Younger patients are less 
subject to variation in access and referral to RRT than older patients.15 Furthermore, 
in this age group the mortality as competing risk for start of RRT is low. Therefore, 
we derive from our data that no effective renoprotective therapies have emerged 
for ADPKD. This may seem to be in contrast to both aforementioned observational 
studies.8,9 However, because of the limited size of their included populations it was 
not possible in these studies to investigate incidence data per age group, as in the 
present study. We found that only after the age of 70 years the RRT incidence rate 
curve has shifted to the right, indicating that in this age group, and especially in 
the very elderly (≥80 years), RRT incidence increased. This is compatible with the 
widespread clinical notion that nowadays more elderly start RRT due to changes in 
RRT take-on policies and due to a reduction in the competing risk of mortality. Our 
interpretation that no effective renoprotective treatment has emerged for ADPKD 
is further supported by the positive association between incidence rate of RRT for 
ADPKD versus non-ADPKD. Countries with a high overall RRT take-on rate also 
have a higher RRT take-on rate for ADPKD. Of note, recent studies suggest that 
vasopressin V2 receptor antagonists and somatostatin analogues ameliorate the 
rate of decline in kidney function in ADPKD patients. However, these treatments are 
not available for clinical use in ADPKD patients yet.16,17
Theoretically there may be several potential explanations as to why the incidence 
rate of RRT has not changed in younger ADPKD patients, despite renoprotection 
that may have been obtained in this age group. First, it could be that survival in 
young ADPKD patients before onset of RRT has improved. Clinical experience and 
scant literature indicate, however, that mortality in ADPKD patients before the age of 
55 years is very low,16,18-20 making it unlikely that this would have biased our results. 
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Second, the average eGFR at which RRT is initiated may have increased, leading 
to an earlier start of RRT. The analysis of eGFR data at start of RRT derived from 
a previous ERA-EDTA registry study showed that in ADPKD patients indeed the 
average eGFR at onset of dialysis was higher in 2003 than in 1999.13 However, this 
difference was small (0.6 ml/min/1.73m2), whereas the rate of eGFR loss in ADPKD 
is between 3 and 6 ml/min/1.73m2 per year.6,7,19,20 These data indicate that a higher 
eGFR at start of RRT translate into an earlier start of RRT of maximum 0.5 year, which 
would not substantially influence our data in Figure 2. Third, there may be relatively 
more ADPKD subjects in the general population at present. Unfortunately, reliable 
data on ADPKD population prevalence over time are unavailable. Since ADPKD is 
a hereditary disease of which most affected subjects know from their relatives that 
it is associated with an unfavorable prognosis, it may be expected that given the 
widespread availability of contraceptives nowadays family size remained the same 
or has become smaller rather than increased. Therefore, we consider it unlikely that 
an increase in ADPKD population prevalence will have biased our interpretation of 
the findings. Finally, in the past ADPKD may have been underdiagnosed. Given the 
family history of these patients, and the ease with which this diagnosis can clinically 
be made using imaging techniques that have been widely available the last 20 
years, also this potential explanation seems unlikely. 
Importantly, with these data we do not imply that strict blood pressure control, ACE 
inhibition, statins, and low salt and low protein diets should not be prescribed. 
Although these regimens may not affect the rate of kidney disease progression in 
ADPKD, they have shown to reduce cardiovascular co-morbidity and mortality in 
patients on RRT 10 as well as before RRT.5,8,21 It should be acknowledged though 
that this has not been investigated in specifically ADPKD patients. However, better 
survival of ADPKD patients prior to start of RRT may explain at least in part the 
increase in RRT incidence rate in elderly ADPKD patients that we observed in 
the present study. Such an increase in survival of pre-ESRD ADPKD patients has 
indeed been reported by others.21
Some other findings in our study are worth to be mentioned. The RRT incidence 
rate for ADPKD in Europe (8.3 pmp in 2006-2010) is equivalent to that in the 
United States (8.1 pmp in 2010), 22 but higher than in Japan (4.8 pmp in 2000).23 
These registries report on sufficiently large datasets to reliably suggest that racial 
differences in ADPKD prevalence or rate of disease progression may exist. During 
the study period, the proportion of ADPKD patients of all patients starting RRT has 
decreased. Our data indicate that this is due to an increase in incidence of RRT 
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for non-ADPKD. The adjusted male/female RRT incidence ratio for ADPKD has 
remained stable in our population at approximately 1.20 during the study period, 
which is comparable to the male/female RRT incidence ratio for ADPKD in Japan 
(1.32) 23 and the USA (1.2-1.3).22 This confirms previous studies that suggested that 
male ADPKD patients have a worse prognosis with respect to renal outcome.2,24 
During the last two decades, the distribution pattern of the different modalities at 
which ADPKD patients started RRT has changed. ADPKD patients received more 
kidney transplantations than non-ADPKD patients from both living and deceased 
donors. This may be due to increased awareness and willingness of non-affected 
family members to donate a kidney. It may also be that ADPKD patients in general 
have less co-morbidity and are therefore more easily accepted on transplant waiting 
lists and because they are often diagnosed many years before ESRD and thus have 
more time for transplant preparation.
This study has a number of limitations. The ERA-EDTA Registry does not contain 
information on actual use of possible renoprotective treatments. However, it 
is generally acknowledged that nowadays ADPKD patients are better treated 
for hypertension and that a larger proportion receives ACE-inhibition.21,25 Not all 
European Union countries participated and complete follow-up was not available 
for each registry during all time periods. For the purpose of this study, however, this 
was not essential, because the conclusions are based on those registries that had 
complete follow-up over time. This study still covers 42% of the inhabitants of the 
European Union representing more than 200 million people, and reports therefore 
on the largest epidemiological dataset on ADPKD thus far. Another strength is that 
we investigated not only overall RRT incidence rates, as previous studies did, but 
also the incidence per RRT treatment modality and compared data obtained in 
ADPKD to non-ADPKD patients.
In summary, this analysis shows that for ADPKD the incidence of RRT, as well as 
the age at which RRT is started, have increased slightly. ADPKD RRT incidence 
rates were stable in younger subjects, but increased in elderly. We interpret these 
findings as that this may be due to more elderly having been selected to start RRT 
or to a decrease in mortality of older patients prior to reaching ESRD rather than as 
effective renoprotective treatments having emerged for ADPKD.
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Supplementary Figure 1. Trends in relative contribution of ADPKD to all incident RRT (%). Data are 
expressed as percentage of the overall population starting renal replacement therapy. Abbreviations: 
AT, Austria; BE, Belgium; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; IT, Italy, 
Calabria; NL, The Netherlands; RO, Romania; SE, Sweden; UK, United Kingdom.
* Coverage of the general population by the renal registry increasing over time, see for details 
Supplementary Table 1. 




















































Supplementary Figure 2. Incidence rate of renal replacement therapy for ADPKD per study period. 
Data are expressed per million of the age related population (pmarp) and given per age group. 
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Deceased donor kidney transplant recipients!
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Supplementary Figure 3. Treatment modality at day 91 after starting renal replacement therapy 
comparing ADPKD versus non-ADPKD patients. Patients receiving a kidney transplant from a living 
donor (upper panel) or deceased donor (lower panel) as percentage of the overall incident renal 
replacement therapy population. Data are the average of the period 2006 through 2010 and adjusted 
for age and sex to the distribution of the 2005 EU27 population. The size of marker denotes the size of 
the general population under study. Abbreviations AT, Austria; BE, Belgium; DK, Denmark; ES, Spain; 
FI, Finland; FR, France; GR, Greece; IT, Italy, Calabria; NL, The Netherlands; RO, Romania; SE, Sweden; 
UK, United Kingdom.
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Supplementary Table 1. Country coverage of RRT information over time (expressed as percentage 
of the whole population per country of which such information is available)
1991-1995 1996-2000 2001-2005 2006-2010
Austria 100 100 100 100
BelgiumA 42.1 100 100 100
Denmark 100 100 100 100
Estonia 100
Finland 100 100 100 100
France 61.2
Greece 100 100 100 100







Spain 45.8B 53.1C 65.3D 73.2E
Sweden 100 100 100 100
The Netherlands 100 100 100 100
United KingdomF 8.8 35.6 77.0 98.5
A First cohort only French-speaking Belgium participates;
B Represents Andalusia, Basque country, Catalonia and Valencian region;
C Represents B and Asturias Cantabria;
D Represents C and Aragon, Castile and León, Castile-La Mancha and Extremadura;
E Represents D and Galicia.
F In the first cohort only Scotland participates
Supplementary Table 2. Incidence of RRT for the ERA-EDTA codes 40 (unspecified polycystic 
kidney disease) and 41 (polycystic kidney disease adult type) expressed as percentage of all 
incident RRT patients.
1991-1995 1996-2000 2001-2005 2006-2010
40 41 40 41 40 41 40 41
Austria 2.7 3.2 1.9 4.1 1.4 4.0 1.3 3.6
BelgiumA 0.7 5.8 0.8 5.7 0.8 4.3 0.5 4.8
Denmark 0.6 7.7 0.6 6.3 0.4 5.8 0.3 6.0
Finland 0.3 9.0 0.5 9.2 0.5 8.2 0.6 8.1
France 0.0 6.4
Greece 0.3 6.7 0.3 5.5 0.2 4.3 0.2 3.9
Italy, Calabria 0.2 5.4 0.6 6.1 0.5 4.8
Romania 0.5 4.7
Spain 0.5B 8.3B 0.4C 7.4C 0.2D 6.7D 0.3E 6.7E
Sweden 2.4 5.0 1.5 5.3 1.0 6.1 0.6 6.8
The Netherlands 1.4 7.0 1.1 6.1 1.1 6.3 0.8 5.4
United KingdomF 0.2 6.9 0.3 6.5 0.2 6.3 0.2 6.3
A First cohort only French-speaking Belgium participates;
B Represents Andalusia, Basque country, Catalonia and Valencian region;
C Represents B and Asturias Cantabria;
D Represents C and Aragon, Castile and León, Castile-La Mancha and Extremadura;
E Represents D and Galicia.
F In the first cohort only Scotland participates
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